1. Comparative study between deep learning and QSAR classifications for TNBC inhibitors and novel GPCR agonist discovery.
- Author
-
Tsou LK, Yeh SH, Ueng SH, Chang CP, Song JS, Wu MH, Chang HF, Chen SR, Shih C, Chen CT, and Ke YY
- Subjects
- Algorithms, Drug Discovery methods, Humans, Neural Networks, Computer, Antineoplastic Agents therapeutic use, Deep Learning, Receptors, G-Protein-Coupled agonists, Triple Negative Breast Neoplasms drug therapy
- Abstract
Machine learning is a well-known approach for virtual screening. Recently, deep learning, a machine learning algorithm in artificial neural networks, has been applied to the advancement of precision medicine and drug discovery. In this study, we performed comparative studies between deep neural networks (DNN) and other ligand-based virtual screening (LBVS) methods to demonstrate that DNN and random forest (RF) were superior in hit prediction efficiency. By using DNN, several triple-negative breast cancer (TNBC) inhibitors were identified as potent hits from a screening of an in-house database of 165,000 compounds. In broadening the application of this method, we harnessed the predictive properties of trained model in the discovery of G protein-coupled receptor (GPCR) agonist, by which computational structure-based design of molecules could be greatly hindered by lack of structural information. Notably, a potent (~โ500 nM) mu-opioid receptor (MOR) agonist was identified as a hit from a small-size training set of 63 compounds. Our results show that DNN could be an efficient module in hit prediction and provide experimental evidence that machine learning could identify potent hits in silico from a limited training set.
- Published
- 2020
- Full Text
- View/download PDF